3KY:F:F-HANSOH PHARMAC. HD-00001 (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2.22

Change

0.00 (0.00)%

Market Cap

USD 13.31B

Volume

14.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 73.13B
MRK:F Merck & Company Inc

N/A

USD 72.76B
H6D0:F Haleon PLC

N/A

USD 42.81B
H6D:F Haleon PLC

N/A

USD 42.44B
TKDA:F Takeda Pharmaceutical Company ..

N/A

USD 41.84B
TEV:F Teva Pharmaceutical Industries..

N/A

USD 18.06B
RDDA:F Dr. Reddy's Laboratories Limit..

N/A

USD 12.12B
SH0:F Shionogi & Co. Ltd

N/A

USD 11.31B
NB3:F Neurocrine Biosciences Inc

N/A

USD 10.87B
EII:F Eisai Co. Ltd

N/A

USD 10.32B

ETFs Containing 3KY:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.37% 79% B- 88% B+
Dividend Return 20.93% 59% D- 76% C+
Total Return 56.29% 78% C+ 86% B+
Trailing 12 Months  
Capital Gain 88.14% 91% A- 95% A
Dividend Return 29.08% 61% D- 76% C+
Total Return 117.22% 89% A- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.19% 81% B- 72% C
Dividend Return 14.25% 77% C+ 70% C-
Total Return 3.06% 55% F 66% D+
Risk Return Profile  
Volatility (Standard Deviation) 30.46% 56% F 42% F
Risk Adjusted Return 46.78% 77% C+ 67% D+
Market Capitalization 13.31B 97% N/A 88% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.